Welcome to our dedicated page for UNITEDHEALTH GROUP SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITEDHEALTH GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITEDHEALTH GROUP's regulatory disclosures and financial reporting.
Michele J. Hooper, a director of UnitedHealth Group (UNH), received 236 shares on 09/23/2025 as dividend equivalents tied to vested deferred stock units; the reporting indicates these dividend equivalents are immediately vested and carry the same terms as the underlying deferred stock units. After the transaction, Hooper beneficially owned 40,715 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025. No cash consideration was paid for the 236 shares, consistent with dividend-equivalent treatment.
Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported a transaction on Form 4 showing the acquisition of 49 shares of Common Stock on 09/23/2025 at no cash price. The filing explains these 49 shares represent dividend equivalents paid on vested deferred stock units, which are immediately vested and subject to the same terms as the underlying units. Following the transaction, Mr. McNabb beneficially owns 14,052 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025.
UnitedHealth Group (UNH) reporting person Charles D. Baker received 1,256 shares of common stock as dividend equivalents on vested deferred stock units. The shares were issued through an acquisition transaction coded A (dividend equivalents) on 09/23/2025 at no cash price ($0), and the ownership is held directly. The filing notes these dividend equivalents become immediately vested and carry the same terms as the underlying deferred stock units. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
John H. Noseworthy, M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition on 09/23/2025. The filing shows 39 shares of Common Stock were acquired at a reported price of $0, described as dividend equivalents paid on vested deferred stock units that are immediately vested and subject to the same terms as the underlying deferred stock units. After the transaction, Dr. Noseworthy beneficially owned 6,432 shares of UNH. The Form 4 was signed by an attorney‑in‑fact on 09/25/2025.
Valerie C. Montgomery Rice M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition of 40 shares of common stock on 09/23/2025. The shares were recorded as dividend equivalents on vested deferred stock units and carried a $0 price; the filing shows 6,627 shares owned after the transaction. The dividend equivalents are immediately vested and subject to the same terms as the underlying deferred stock units. The Form 4 was signed by attorney‑in‑fact Faraz A. Choudhry on 09/25/2025.
Erin L. McSweeney, Executive Vice President and Chief People Officer of UnitedHealth Group (UNH), reported a non‑cash acquisition on 09/23/2025 consisting of 36.837 shares of common stock recognized as dividend equivalents on outstanding restricted stock units. The reported price is $0 because these shares represent dividend equivalents rather than a market purchase. Following this issuance, McSweeney beneficially owns 11,154.072 shares. The filing notes the dividend equivalents follow the same vesting terms as the underlying restricted stock units and are forfeitable if those units do not vest.
Christopher R. Zaetta, EVP & Chief Legal Officer of UnitedHealth Group (UNH), received 42.53 dividend-equivalent shares on 09/23/2025 that were paid on outstanding restricted stock units and are subject to the same vesting and forfeiture terms as the underlying RSUs. The transaction was reported on a Form 4 executed by an attorney-in-fact on 09/25/2025. The reported shares were issued at a $0 price as dividend equivalents and increase the reporting person’s beneficial ownership to 10,283.276 shares following the transaction.
UnitedHealth Group (UNH) Form 4: This filing reports a non-derivative acquisition by Thomas E. Roos, Chief Accounting Officer, via an authorized filing on behalf of the reporting person. On 09/23/2025 the report shows an acquisition of 22.357 units recorded as dividend equivalents on outstanding restricted stock units, with a reported price of $0 because these are dividend-equivalent payments tied to RSUs and subject to the same vesting and forfeiture terms as the underlying awards. Following the transaction, the reporting person beneficially owned 29,593.519 shares, which includes shares acquired through UnitedHealth’s Employee Stock Purchase Plan. The filing was signed by an attorney-in-fact on 09/25/2025.
Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), filed a Form 4 reporting changes in his beneficial ownership. The filing shows a transaction dated 09/11/2025 reporting 27 shares of Common Stock with transaction code S at a price of $356.05. The Form reports that following the reported transaction the reporting person had 1,248 shares of Common Stock beneficially owned indirectly (by trust). The form also explains that on 08/01/2025 the reporting person acquired indirect beneficial ownership of 27 UNH shares by inheritance, an acquisition the filer states was exempt from reporting under Rules 16a-3 and 16b-5.
UnitedHealth Group (UNH) filer submitted a Form 144 reporting a proposed sale of company common stock. The notice shows 27 shares intended for sale on the NYSE through J.P. Morgan Securities LLC with an aggregate market value of $9,363.06 and an approximate sale date of 09/11/2025. The securities were acquired by transfer on 08/01/2025 from the "Barbara L S Schadt Terminating Trust UAD 12-16-2015" and payment/consideration is listed as N/A. The form indicates no securities sold in the prior three months and contains standard signature and representation language. Some filer identifiers and contact details are not provided in the content.